Lamotrigine Augmentation in Resistant Depression

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Louisiana State University Health Sciences Center in New Orleans
ClinicalTrials.gov Identifier:
NCT00901407
First received: May 11, 2009
Last updated: May 12, 2009
Last verified: May 2009
  Purpose

This study is intended to evaluate the efficacy and safety of lamotrigine as an antidepressant augmentation agent in a sample of individuals with major depression and a history of both prior non-response and prospective failure to respond to at least one adequate trial of an antidepressant (for a total of two failed trials).


Condition Intervention
Unipolar Depression
Drug: lamotrigine
Drug: placebo
Drug: paroxetine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression

Resource links provided by NLM:


Further study details as provided by Louisiana State University Health Sciences Center in New Orleans:

Primary Outcome Measures:
  • MADRS score [ Time Frame: weeks 0 (randomization); 8, 9, 10, 12, 14, 16, 18, and 20 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Ham-D score [ Time Frame: weeks 0 (randomization); 2, 4, 6, 8, 9, 10, 12, 14, 16, and 18 ] [ Designated as safety issue: Yes ]
  • CGI-S and CGI-I [ Time Frame: weeks 0 (randomization); 8, 9, 10, 12, 14, 16, 18 and 20 ] [ Designated as safety issue: Yes ]

Enrollment: 138
Study Start Date: December 2003
Study Completion Date: April 2007
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
lamotrigine
Drug: lamotrigine
lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
Other Name: Lamictal
Drug: paroxetine
open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Other Name: paxil
Placebo Comparator: 2
placebo
Drug: placebo
placebo: 1-2 tablets bid; 10 weeks
Drug: paroxetine
open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Other Name: paxil

Detailed Description:

The study will consist of four phases: screening, open-label, double-blind and discontinuation phases. After screening to ensure that subjects meet the study criteria, individuals will enter an open-label (flexible-dose) trial of paroxetine-CR given in dosages up to 62.5 mg for a period of eight weeks. Paroxetine may be substituted for paroxetine-CR in dosages up to 50 mg. Subjects may be switched from paroxetine-CR to the bioequivalent dose of paroxetine due to drug supply disruption but should not be switched back to paroxetine-CR. Subjects are not allowed to switch from paroxetine to paroxetine-CR. Subjects who start on paroxetine at the first visit must remain on paroxetine for the duration of the study. At the discretion of the investigator, additional monitoring or interim visits may be needed for subjects who require a switch from paroxetine-CR to paroxetine. Those individuals who fail to respond adequately will then continue into the second phase (double-blind portion) of the study, in which participants will continue on either paroxetine-CR or paroxetine, and will be randomized to either placebo or lamotrigine in a flexible-dose design up to 400mg for a 10-week period. Subjects will remain on the same dose of paroxetine-CR or paroxetine that they were taking at the final visit in the first phase of the study (Visit 5/Week 8). The study medications will be discontinued following the final study visit (Visit 11/Week 18 or the early termination visit). Paroxetine-CR or paroxetine may be continued in the dosages used during the study after completion of the protocol if, in the judgment of the investigator, the subject has shown a partial response to treatment with the drug. The lamotrigine (or placebo) dose will be decreased by half for one week and then discontinued. Subjects will return two weeks post-study and four weeks post study for follow up visits consisting of safety evaluations. In addition, a MADRS and CGI should be performed at the two-week post study follow up visit. The visit at four weeks post study may be omitted if the 3rd and 4th week of taper are not needed. The decision to restart lamotrigine at that time would also be up to the investigator, but the dosage of lamotrigine would have to be titrated in the first month per the manufacturer's clinical trial program. This is necessary since all subjects will be discontinuing from the drug following Visit 11/Week 18 or the early termination visit in order to maintain the blind at the conclusion of each subject's participation in the study. Subjects who are discontinued from paroxetine-CR at dosages of 25 mg/day or higher should undergo a gradual dose reduction of 12.5 mg per week rather than abrupt cessation. Subjects who are discontinued from paroxetine at dosages of 20 mg/day or higher should undergo a gradual dose reduction of 10 mg per week rather than abrupt cessation.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects, age 18-65
  2. A current primary diagnosis of unipolar major depression based on certain criteria
  3. Have a score of > 18 on the 17-item Hamilton Depression scale
  4. A history of prior failure of at least one adequate trial of an FDA-approved antidepressant. The antidepressant failure must have occurred within the current episode of major depression
  5. Females of childbearing potential will be allowed as long as they are taking adequate contraceptive precautions

Exclusion Criteria:

  1. A primary Axis I diagnosis other than primary unipolar major depression
  2. A history suggestive of hypomania or mania during the current episode or during the person's lifetime
  3. A history of psychosis, dementia, organic affective disorders or alcohol and/or substance abuse in the previous six months

    • Individuals with a current or past diagnosis of schizoid, schizotypal, borderline or antisocial or any other current or past severe personality disorder
    • Individuals with a current or past diagnosis of schizophrenia or schizoaffective disorder
  4. A history of failure to respond to electroconvulsive therapy during the current or any prior lifetime episode of major depression
  5. A history of failure of a prior adequate trial of paroxetine or paroxetine-CR for the treatment of Major Depression
  6. Significant, coexisting medical conditions that might make it unsafe to take either of the study medications, or in which any average reasonable clinician would assume that the medical condition may, in fact, be exacerbating the current episode of depression or impede the person's ability to recover fully from their depressive illness
  7. Presence of significant medical abnormalities on baseline laboratory values or physical examination, including vital signs

    • Individuals with any significant abnormalities of thyroid function
    • Subjects on thyroid supplementation must have been on a stable dose for six months prior to the screening visit
  8. Individuals who will require concomitant psychotropic medications, including benzodiazepines

    • Subjects with severe insomnia will be allowed to take a maximum of 10 mg of zolpidem on two nights weekly at the investigator's discretion.
    • Zolpidem may not be taken on the night before the study visit.
    • Each dose of zolpidem should be listed on the concurrent medication case report form
  9. Medications likely to cause significant effects on mood and anxiety are also excluded
  10. Individuals with a positive urine drug screen for drugs of abuse at the screening visit
  11. Use during the time of the study of any medications known to affect the metabolism of lamotrigine

    • Individuals on valproate and carbamazepine will be specifically excluded
    • Investigators should be aware that oral contraceptives have been reported to lower the levels of lamotrigine, but any change in dosing is left to the judgment of the investigator
  12. Subjects who have taken other psychoactive drugs within certain time frames of the screening visit
  13. The presence of significant risk of suicide
  14. Pregnant females or those who are breastfeeding infants
  15. A history of hypersensitivity or intolerance to either of the study medications, lamotrigine or paroxetine or paroxetine-CR
  16. Subjects initiating or terminating psychotherapy within 12 weeks of the screening visit
  17. Individuals who are currently on disability for a psychiatric disorder, or who are in any other way likely to experience considerable secondary gain from the persistence of their psychiatric illness, such as pending legal litigation of any type
  18. Individuals who in the opinion of the investigator would not be able to understand or comply with the study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00901407

Locations
United States, Louisiana
LSUHSC- New Orleans
New Orleans, Louisiana, United States, 70115
Sponsors and Collaborators
Louisiana State University Health Sciences Center in New Orleans
GlaxoSmithKline
Investigators
Principal Investigator: James G. Barbee, MD Louisiana State University Health Sciences Center in New Orleans
  More Information

Publications:
Barbee, J.G., Jamhour, N,J., Stewart, J.W., Shelton, R.C., Reimherr, F.W., Thompson, P.M., Conrad, E.J. &Thompson, T.R. (2007, May). Lamotrigine as an antidepressant augmentation in treatment refractory unipolar depression. Poster session presented at the annual meeting of the American Psychiatric Association, San Diego, CA.
Barbee, J.G., Jamhour, N,J. & Conrad, E.J. (2007, June). Predictors of response to lamotrigine augmentation in treatment refractory unipolar depression. Poster session presented at the annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: James G. Barbee, IV, MD, LSUHSC
ClinicalTrials.gov Identifier: NCT00901407     History of Changes
Other Study ID Numbers: LMC-R93
Study First Received: May 11, 2009
Last Updated: May 12, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Louisiana State University Health Sciences Center in New Orleans:
augmentation
depression
resistance

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Paroxetine
Lamotrigine
Anticonvulsants
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Calcium Channel Blockers
Membrane Transport Modulators
Cardiovascular Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers

ClinicalTrials.gov processed this record on October 19, 2014